Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Nonhematologic Malignancies 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neurofibrosarcoma 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Meningeal Neoplasms 1Lymphoma 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 5avelumab 4Ipilimumab 4Radiotherapy 2Radiosurgery 2ALT-803 2tremelimumab 1talimogene laherparepvec 1sapanisertib 1prednylidene 1poly ICLC 1lenvatinib 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1deltacortene 1cemiplimab 1cabozantinib 1bempegaldesleukin 1atezolizumab 1Tacrolimus 1Radiation Dose Hypofractionation 1Radiation 1Prednisone 1Interferon-gamma 1Interferon-beta 1CTLA-4 Antigen 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Merkel Cell × sapanisertib × Clear all
NCT02514824 2020-12-29

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
9 enrolled 10 charts
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡